NasdaqGM:SIONBiotechs
Assessing Sionna Therapeutics (SION) Valuation After A Sharp Share Price Move And Elevated Price To Book Ratio
Why Sionna Therapeutics (SION) is on investors’ radar today
Sionna Therapeutics (SION) has attracted fresh attention after a recent 16.1% one day move, as investors reassess this clinical stage cystic fibrosis developer.
See our latest analysis for Sionna Therapeutics.
That 16.1% one day share price return comes on top of a 46.9% 90 day share price return and a 10.2% year to date gain, suggesting momentum has been building rather than fading, with the stock now at $43.21.
If you are looking...